Regeneron ubamatamab shows durable responses in LGSOC study
Regeneron said ubamatamab (MUC16xCD3) showed a high rate of durable responses in an initial study of patients with advanced low-grade serous ovarian cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.